Tag: Bezlotoxumab

While standard over-the-counter and oral prescription medications are the primary treatment for most diarrhea cases, injectable medications are available for specific, severe conditions. The question of 'is there any injection to stop diarrhea?' arises when conventional treatments fail, such as with certain tumor-related or chemotherapy-induced conditions.

Zinplava (bezlotoxumab) is a human monoclonal antibody approved by the FDA to help reduce the recurrence of *Clostridioides difficile* infection (CDI) in high-risk adult patients. This medication is administered as a single, one-hour intravenous infusion during a course of antibacterial treatment for CDI. Knowing what to expect after a Zinplava infusion can help patients and their caregivers monitor for side effects and ensure a smoother recovery process.

Recurrent *Clostridioides difficile* (*C. diff*) infection affects approximately 1 in 5 patients who contract the illness. To combat this, the landscape of treatment is rapidly shifting away from repeated courses of antibiotics toward innovative, targeted therapies. These new approaches focus on restoring the gut microbiome and neutralizing the toxins responsible for infection, directly answering the question: 'What is the new treatment for C. diff?'.

While oral antibiotics like vancomycin and fidaxomicin are the primary treatment for active *C. difficile* infection (CDI), intravenous (IV) infusions are used in specific circumstances, such as for severe, complicated cases or to prevent recurrence. The answer to **'what is the infusion for C. difficile?'** involves understanding the different roles of medications, including the use of IV metronidazole for severe illness and the recently discontinued bezlotoxumab for preventing recurrence.